Andreas Ejlegård: Rebalancing Thrombosis and Hemostasis Through Mechanistic Innovation
Andreas Ejlegård, Sales Development Manager at Rexel Sverige, shared a post on LinkedIn about recent articles by Michael Holinstat et al. , adding:
“Congratulations to Michael Holinstat on being named a 2026 Fellow of ACTS.
A well deserved recognition of his contributions to clinical and translational science.
His work with Cereno Scientific is particularly compelling across multiple programs.
With CS585, we are seeing a novel prostacyclin receptor approach that could prevent thrombosis without the traditional bleeding trade off.
Notably, the CS585 study was published in Blood, underscoring both the scientific quality and relevance of the findings.
At the same time, the recently published CS014 study in the Journal of Thrombosis and Haemostasis strengthens the broader thesis.
CS014, a next generation HDAC inhibitor, demonstrates potent antithrombotic effects while preserving normal haemostasis, effectively separating efficacy from bleeding risk.
Taken together, this is not incremental innovation.
It reflects a coordinated effort to target thrombosis, fibrosis, and vascular dysfunction at a mechanistic level.
These programs begin to approach something close to a ‘holy grail’ in cardiovascular medicine: effective thrombosis prevention without increased bleeding risk.”
1.Title: The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor
Authors: Livia Stanger, Adriana Yamaguchi, Pooja Yalavarthi, Sylviane Lambert, Devin Gilmore, Andrew Rickenberg, Catherine Luke, Kiran Kumar, Andrea T Obi, Andrew White, Niklas Bergh, Björn Dahlöf, Michael Holinstat
2.Title: Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
Authors: Livia Stanger, Pooja Yalavarthi, Reheman Adili, Devin Gilmore, Timothy Hoang, Avery Campbell, Paul Krenik, David Gustafsson, Jan Fryklund, Tomas Fex, Nicholas Oakes, Jonas Faijerson Säljö, Björn Dahlöf, Joan Beckman, Michael Holinstat
Stay updated with all scientific advances Hemostasis Today.
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care